Multiple Sclerosis: New Insights and Trends

References

1. ↵
   Rodriguez M, Siva A, Ward J, et al. Impairment, disability, and handicap in multiple sclerosis: a population-based study in Olmsted County, Minnesota. Neurology 1994;44:28–33

   Abstract/FREE Full Text
2. ↵
   Hauser S. Multiple sclerosis and other demyelinating diseases. In: Isselbacher KJ, Martin JB, Fauci AS, et al, eds. Harrison’s principles of internal medicine. New York: McGraw-Hill;1994 :2287–95
3. ↵
   Oksenberg JR, Hauser SL. Genetics of multiple sclerosis. Neurol Clin 2005;23:61–75

   CrossRefPubMedWeb of Science
4. ↵
   McAlpine D. Multiple sclerosis: a reappraisal. Edinburgh: Churchill Livingstone;1972
5. ↵
   Reingold SC. Fatigue and multiple sclerosis. MS News Br Mult Scler Soc 1990;142:30–31
6. ↵
   Bagert B, Camplair P, Bourdette D. Cognitive dysfunction in multiple sclerosis: natural history, pathophysiology and management. CNS Drugs 2002;16:445–55

   CrossRefPubMedWeb of Science
7. ↵
   Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112:133–46

   Abstract/FREE Full Text
8. ↵
   Montalban X. Primary progressive multiple sclerosis. Curr Opin Neurol 2005;18:261–66

   PubMedWeb of Science
9. ↵
   Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907–11

   Abstract/FREE Full Text
10. ↵
    Young IR, Hall AS, Pallis CA, et al. Nuclear magnetic resonance imaging of the brain in multiple sclerosis. Lancet 1981;2(8255):1063–66
11. ↵
    Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997;120:2059–69

    Abstract/FREE Full Text
12. ↵
    McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001;50:121–27

    CrossRefPubMedWeb of Science
13. ↵
    Poser CM. Diagnostic criteria for multiple sclerosis: an addendum. Ann Neurol 1987;22:773

    PubMed
14. ↵
    Tintore M, Rovira A, Martinez MJ, et al. Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR Am J Neuroradiol 2000;21:702–06

    Abstract/FREE Full Text
15. ↵
    Dalton CM, Brex PA, Miszkiel KA, et al. Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann Neurol 2002;52:47–53

    CrossRefPubMedWeb of Science
16. Tintore M, Rovira A, Rio J, et al. New diagnostic criteria for multiple sclerosis: application in first demyelinating episode. Neurology 2003;60:27–30

    Abstract/FREE Full Text
17. ↵
    Barkhof F, Rocca M, Francis G, et al. Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a. Ann Neurol 2003;53:718–24

    CrossRefPubMedWeb of Science
18. ↵
    Dalton CM, Brex PA, Miszkiel KA, et al. New T2 lesions enable an earlier diagnosis of multiple sclerosis in clinically isolated syndromes. Ann Neurol 2003;53:673–76

    CrossRefPubMedWeb of Science
19. ↵
    Frohman EM, Goodin DS, Calabresi PA, et al. The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2003;61:602–611

    Abstract/FREE Full Text
20. ↵
    Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria.” Ann Neurol 2005;58:840–46

    CrossRefPubMedWeb of Science
21. ↵
    Bot JC, Barkhof F, Polman CH, et al. Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination. Neurology 2004;62:226–33

    Abstract/FREE Full Text
22. ↵
    Bot JC, Barkhof F, Lycklama a Nijeholt G, et al. Differentiation of multiple sclerosis from other inflammatory disorders and cerebrovascular disease: value of spinal MR imaging. Radiology 2002;223:46–56

    CrossRefPubMedWeb of Science
23. ↵
    Pashenkov M, Teleshova N, Link H. Inflammation in the central nervous system: the role for dendritic cells. Brain Pathol 2003;13:23–33

    PubMedWeb of Science
24. ↵
    Hafler DA, Slavik JM, Anderson DE, et al. Multiple sclerosis. Immunol Rev 2005;204:208–231

    CrossRefPubMedWeb of Science
25. ↵
    Link H. The cytokine storm in multiple sclerosis. Mult Scler 1998;4:12–15

    Abstract/FREE Full Text
26. ↵
    Lassmann H. Pathology of multiple sclerosis. In: Compston A, Ebers G, Lassmann H, et al, eds. McAlpine’s multiple sclerosis. London: Churchill Livingstone;1998 :323–57
27. ↵
    Steinman L. Multiple sclerosis: a two-stage disease. Nat Immunol 2001;2:762–64

    CrossRefPubMedWeb of Science
28. ↵
    Lassmann H, Bruck W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 2001;7:115–21

    CrossRefPubMedWeb of Science
29. ↵
    Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707–17

    CrossRefPubMedWeb of Science
30. ↵
    Lassmann H. Hypoxia-like tissue injury as a component of multiple sclerosis lesions. J Neurol Sci 2003;206:187–91

    CrossRefPubMedWeb of Science
31. ↵
    Trapp BD, Ransohoff R, Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr Opin Neurol 1999;12:295–302

    CrossRefPubMedWeb of Science
32. ↵
    Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278–85

    CrossRefPubMedWeb of Science
33. ↵
    Kapoor R, Davies M, Blaker PA, et al. Blockers of sodium and calcium entry protect axons from nitric oxide-mediated degeneration. Ann Neurol 2003;53:174–80

    CrossRefPubMedWeb of Science
34. ↵
    Werner P, Pitt D, Raine CS. Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 2001;50:169–80

    CrossRefPubMedWeb of Science
35. ↵
    Craner MJ, Newcombe J, Black JA, et al. Molecular changes in neurons in multiple sclerosis: altered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na+/Ca2+ exchanger. Proc Natl Acad Sci USA 2004;101:8168–73

    Abstract/FREE Full Text
36. ↵
    Brownell B, Hughes JT. The distribution of plaques in the cerebrum in multiple sclerosis. J Neurol Neurosurg Psychiatry 1962;25:315–20

    FREE Full Text
37. ↵
    Kidd D, Barkhof F, McConnell R, et al. Cortical lesions in multiple sclerosis. Brain 1999;122:17–26

    Abstract/FREE Full Text
38. ↵
    Bo L, Vedeler CA, Nyland H, et al. Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult Scler 2003;9:323–31

    Abstract/FREE Full Text
39. ↵
    Peterson JW, Bo L, Mork S, et al. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001;50:389–400

    CrossRefPubMedWeb of Science
40. ↵
    Calabresi PA. Considerations in the treatment of relapsing-remitting multiple sclerosis. Neurology 2002;58(8 suppl 4):S10–22